Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2022

Primary Completion Date

August 1, 2026

Study Completion Date

October 1, 2026

Conditions

Opioid Induced Respiratory DepressionChronic Opioid Use

Interventions

DRUG

Narcan 40 MG/ML Nasal Spray

naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously

DRUG

Naloxone Hydrochloride

Naloxone 0.4mg/mL

DRUG

Nalmefene HCl injection

Nalmefene 1 ng/mL

Trial Locations (1)

RECRUITING

Leiden University Medical Center, Leiden

All Listed Sponsors

collaborator

U.S. Food and Drug Administration (FDA)

UNKNOWN

lead

Leiden University Medical Center

OTHER

NCT05338632 - Reversal of Opioid-induced Respiratory Depression With Opioid Antagonists | Biotech Hunter | Biotech Hunter